Constellation Pharmaceuticals, Inc. (CNST): Price and Financial Metrics

Constellation Pharmaceuticals, Inc. (CNST): $33.99

0.02 (+0.06%)

POWR Rating

Component Grades








Add CNST to Watchlist
Sign Up

CNST Price/Volume Stats

Current price $33.99 52-week high $39.30
Prev. close $33.97 52-week low $17.00
Day low $33.97 Volume 1,314,700
Day high $34.05 Avg. volume 940,325
50-day MA $28.38 Dividend yield N/A
200-day MA $27.15 Market Cap 1.63B

CNST Stock Price Chart Interactive Chart >

Constellation Pharmaceuticals, Inc. (CNST) Company Bio

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company’s lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors and/or hematological malignancies; and CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. The company was founded in 2008 and is based in Cambridge, Massachusetts.

CNST Latest News Stream

Event/Time News Detail
Loading, please wait...

CNST Latest Social Stream

Loading social stream, please wait...

View Full CNST Social Stream

Latest CNST News From Around the Web

Below are the latest news stories about Constellation Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNST as an investment opportunity.

MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology

Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty PharmaPLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its previously announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) ("Constellation") for $34.

Yahoo | July 15, 2021

Should I Avoid Constellation Pharmaceuticals, Inc. (CNST)?

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

Yahoo | July 13, 2021

Lifshitz Law Firm, P.C. Announces Investigation of ALTA, CAI, CNST, and IKNX

NEW YORK, NY / ACCESSWIRE / July 7, 2021 /Altabancorp (NasdaqCM:ALTA)Lifshitz Law Firm, P. announces investigation into possible breach of fiduciary duties in connection with the merger of ALTA with GBCI.

Yahoo | July 7, 2021

INVESTIGATION ALERT: Halper Sadeh LLP Investigates IKNX, MPB, JAX, CNST; Shareholders are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | July 3, 2021

Lifshitz Law Firm, P.C. Announces Investigation of CNST, FFWM, SLCT, and GRA

NEW YORK, NY / ACCESSWIRE / July 2, 2021 / Lifshitz Law Firm, P.:Constellation Pharmaceuticals, Inc.

Yahoo | July 2, 2021

Read More 'CNST' Stories Here

CNST Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 57.80%
5-year 185.63%
2023 N/A
2022 N/A
2021 0.00%
2020 -38.87%
2019 1,074.81%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!